Cipla Q4 profit lags due to one-off charges in Europe, emerging markets | Reuters

MUMBAI Cipla Ltd, India's fifth-largest drugmaker by sales, reported a 69 percent fall in its quarterly profit, well below analysts' forecasts, due to one-off costs related to its business in Europe and some emerging markets. The company is working on exiting some emerging markets 'due to complexities', and changing its European business from direct-to-consumer to business-to-business, Chief Operating Officer Umang Vohra told analysts on a conference call on Tuesday

Reuters May 24, 2016 20:20:14 IST
Cipla Q4 profit lags due to one-off charges in Europe, emerging markets 
| Reuters

Cipla Q4 profit lags due to oneoff charges in Europe emerging markets 
 Reuters

MUMBAI Cipla Ltd, India's fifth-largest drugmaker by sales, reported a 69 percent fall in its quarterly profit, well below analysts' forecasts, due to one-off costs related to its business in Europe and some emerging markets.

The company is working on exiting some emerging markets "due to complexities", and changing its European business from direct-to-consumer to business-to-business, Chief Operating Officer Umang Vohra told analysts on a conference call on Tuesday.

"We are looking to significantly simplify the way we work in emerging markets," Vohra said. Any more one-off charges related to these changes are unlikely in the coming quarters, he added.

Cipla, a big producer of HIV/AIDS and respiratory medicines, expects earnings before interest, tax, and depreciation to grow about 15 to 20 percent in fiscal 2017, from the 25.02 billion rupees reported for fiscal 2016, Vohra said.

The company reported January-March net profit of 808.7 million rupees ($12 million), while analysts polled by Thomson Reuters expected 3.79 billion rupees. Some of one-off charges were also related to non-moving inventory, Vohra said.

Sales in India, Cipla's biggest market, rose 16 percent, while those from exports grew 3 percent.

Cipla is working on building its business in the United States, a market in which it is a late entrant compared with most of its Indian peers. But like most of them, it faces regulatory challenges in that market. The U.S. Food and Drug Administration sent Cipla a notice last October about violations of manufacturing standards the agency found at the company's Indore plant in central India.

Cipla has sent its final response to the FDA's concerns, and is awaiting word from the agency, Vohra said.

The company expects to file about 20 to 25 products for U.S. approval this year, including respiratory and oncology drugs, he added.

($1 = 67.7027 Indian rupees)

(Reporting by Zeba Siddiqui in Mumbai; Editing by Alexander Smith and David Evans)

This story has not been edited by Firstpost staff and is generated by auto-feed.

Updated Date:

also read

Tokyo Olympics 2020: Mexico thrash France as Richarlison hat-trick helps Brazil hand Germany 4-2 loss
Sports

Tokyo Olympics 2020: Mexico thrash France as Richarlison hat-trick helps Brazil hand Germany 4-2 loss

Sylvain Ripoll's France are looking for a first Olympic medal since winning gold in 1984, but collapsed in the second half at Tokyo Stadium.

US lowers travel advisory for India: Why this change was made and travel situation with other countries
World

US lowers travel advisory for India: Why this change was made and travel situation with other countries

The United States' travel advisory comes as India recorded just 30,093 new coronavirus infections, its lowest in 125 days

Tour de France 2021: UAE Team Emirates' Tadej Pogacar claims second successive title in dominant fashion
Sports

Tour de France 2021: UAE Team Emirates' Tadej Pogacar claims second successive title in dominant fashion

Pogacar stole in at the 11th hour to win the 2020 edition, but this year he stamped his authority in the first week and will pull on the yellow jersey beneath the Arc de Triomphe as the undisputed champion aged just 22.